A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions.


Journal

CPT: pharmacometrics & systems pharmacology
ISSN: 2163-8306
Titre abrégé: CPT Pharmacometrics Syst Pharmacol
Pays: United States
ID NLM: 101580011

Informations de publication

Date de publication:
06 2021
Historique:
revised: 08 03 2021
received: 30 12 2020
accepted: 01 04 2021
pubmed: 5 5 2021
medline: 22 1 2022
entrez: 4 5 2021
Statut: ppublish

Résumé

The success of applications of physiologically-based pharmacokinetic (PBPK) modeling in drug development and drug labeling has triggered regulatory agencies to demand rigorous demonstration of the predictive capability of the specific PBPK platform for a particular intended application purpose. The effort needed to comply with such qualification requirements exceeds the costs for any individual PBPK application. Because changes or updates of a PBPK platform would require (re-)qualification, a reliable and efficient generic qualification framework is needed. We describe the development and implementation of an agile and sustainable technical framework for automatic PBPK platform (re-)qualification of PK-Sim

Identifiants

pubmed: 33946131
doi: 10.1002/psp4.12636
pmc: PMC8213412
doi:

Substances chimiques

Cytochrome P-450 CYP3A EC 1.14.14.1
CYP3A4 protein, human EC 1.14.14.55

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

633-644

Informations de copyright

© 2021 Pharmacometrics/Modeling & Simulation, Research & Development, Pharmaceuticals, Bayer AG. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Références

CPT Pharmacometrics Syst Pharmacol. 2019 May;8(5):296-307
pubmed: 30762305
Drug Metab Dispos. 2011 Feb;39(2):170-3
pubmed: 21036951
Clin Pharmacol Ther. 2018 Jul;104(1):188-200
pubmed: 29027194
Eur J Clin Pharmacol. 1998 Mar;54(1):53-8
pubmed: 9591931
Pharmaceutics. 2020 Dec 08;12(12):
pubmed: 33302490
Drug Metab Pharmacokinet. 2020 Feb;35(1):2-11
pubmed: 31996310
Clin Pharmacokinet. 2019 Dec;58(12):1595-1607
pubmed: 31129789
Clin Pharmacol Ther. 2017 Jul;102(1):98-105
pubmed: 27770430
Clin Pharmacokinet. 2020 Nov;59(11):1419-1431
pubmed: 32449077
Clin Pharmacol Ther. 1989 Jul;46(1):99-102
pubmed: 2501060
CPT Pharmacometrics Syst Pharmacol. 2020 Jan;9(1):21-28
pubmed: 31652029
J Clin Pharmacol. 2020 Oct;60 Suppl 1:S160-S178
pubmed: 33205429
CPT Pharmacometrics Syst Pharmacol. 2016 Mar;5(3):93-122
pubmed: 27069774
Drug Metab Dispos. 2018 Oct;46(10):1420-1433
pubmed: 30068519
J Clin Pharmacol. 2019 Sep;59 Suppl 1:S95-S103
pubmed: 31502689
Clin Pharmacol Ther. 1994 May;55(5):481-5
pubmed: 8181191
CPT Pharmacometrics Syst Pharmacol. 2019 Sep;8(9):685-695
pubmed: 31215774
Clin Pharmacol Ther. 2003 Sep;74(3):275-87
pubmed: 12966371
J Pharm Sci. 2019 Jan;108(1):21-25
pubmed: 30385284
CPT Pharmacometrics Syst Pharmacol. 2018 Oct;7(10):647-659
pubmed: 30091221
CPT Pharmacometrics Syst Pharmacol. 2016 Sep;5(9):475-83
pubmed: 27566992
Clin Pharmacol Ther. 2012 Apr;91(4):673-84
pubmed: 22398970
Biopharm Drug Dispos. 2018 Jan;39(1):3-17
pubmed: 28960401
CPT Pharmacometrics Syst Pharmacol. 2019 Dec;8(12):878-882
pubmed: 31671256
Clin Pharmacol Ther. 2017 Apr;101(4):519-530
pubmed: 27943276
Br J Clin Pharmacol. 2008 Oct;66(4):473-84
pubmed: 18537963
Clin Pharmacol Ther. 2011 Jul;90(1):100-8
pubmed: 21562488
Clin Pharmacol Ther. 2006 Apr;79(4):350-61
pubmed: 16580903

Auteurs

Sebastian Frechen (S)

Pharmacometrics/Modeling & Simulation, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.

Juri Solodenko (J)

Pharmacometrics/Modeling & Simulation, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.

Thomas Wendl (T)

Pharmacometrics/Modeling & Simulation, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.

André Dallmann (A)

Pharmacometrics/Modeling & Simulation, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.

Ibrahim Ince (I)

Pharmacometrics/Modeling & Simulation, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.

Thorsten Lehr (T)

Clinical Pharmacy, Saarland University, Saarbrücken, Germany.

Jörg Lippert (J)

Pharmacometrics/Modeling & Simulation, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.

Rolf Burghaus (R)

Pharmacometrics/Modeling & Simulation, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH